Antivirals targeting the polymerase complex of influenza viruses.
Antiviral Res
; 169: 104545, 2019 09.
Article
em En
| MEDLINE
| ID: mdl-31247246
ABSTRACT
Current influenza antivirals have limitations with regard to their effectiveness and the potential emergence of resistance. Encouragingly, several new compounds which inhibit the polymerase of influenza viruses have recently been shown to have enhanced pre-clinical and clinical effectiveness compared to the neuraminidase inhibitors, the mainstay of influenza antiviral therapy over the last two decades. In this review we focus on four compounds which inhibit polymerase function, baloxavir marboxil, favipiravir, pimodivir and AL-794 and discuss their clinical and virological effectiveness, their propensity to select for resistance and their potential for future combination therapy with the most commonly used neuraminidase inhibitor, oseltamivir.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Orthomyxoviridae
/
RNA Polimerases Dirigidas por DNA
/
Neuraminidase
Limite:
Humans
Idioma:
En
Revista:
Antiviral Res
Ano de publicação:
2019
Tipo de documento:
Article